“I am very proud of our team’s performance across every part of the company in 2024,” Dr. Klein said. “We met every one of our planned clinical and regulatory milestones on schedule. Commercially, we outperformed guidance. And we begin 2025 with a strong cash balance, ready to build on our successes. PTC, now stronger and more innovative than ever, will continue to work to bring transformative therapies to the patient communities we serve in 2025 and beyond.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target lowered to $58 from $63 at RBC Capital
- PTC Therapeutics submits NDA for vatiquinone in Friedreich ataxia
- PTC Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
- Cantor Fitzgerald says ‘aggressively’ buy uniQure, PTC Therapeutics
- Biotech Alert: Searches spiking for these stocks today